SCHEMBL15068612

SCHEMBL15068612

CCN1CCC(c2c(N)c3ccccc3oc2=O)C1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 9/20 0.46
KDM4E B2RXH2 8/20 0.46
ALDH1A1 P00352 5/20 0.46
MAPT P10636 5/20 0.43
LMNA P02545 2/20 0.43
PLA2G1B P04054 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
ATG4B Q9Y4P1 1/20 0.43
HSD17B10 Q99714 3/20 0.43
AGTR1 P30556 1/20 0.43
HPGD P15428 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ALOX15 P16050 2/20 0.41
DRD2 P14416 1/20 0.40
SLC6A4 P31645 1/20 0.40
POLB P06746 1/20 0.40
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15068615 0.91 GAA (0.47) GAAKDM4EALDH1A1MAPTLMNA
SCHEMBL15068632 0.85 GAA (0.48) GAAKDM4EALDH1A1MAPTLMNA
SCHEMBL15068897 0.82 GAA (0.50) GAAKDM4EALDH1A1MAPTLMNA
SCHEMBL16671454 0.82 GAA (0.44) GAAKDM4EALDH1A1MAPTLMNA
SCHEMBL15068635 0.76 ALDH1A1 (0.49) GAAKDM4EALDH1A1MAPTLMNA
SCHEMBL16671456 0.73 GAA (0.46) GAAKDM4EALDH1A1MAPTLMNA
SCHEMBL15068899 0.73 GAA (0.51) GAAKDM4EALDH1A1MAPTLMNA
SCHEMBL4069907 0.68 PARP1 (0.52) DRD2
SCHEMBL16671709 0.68 GAA (0.39) GAAKDM4EALDH1A1MAPTLMNA
SCHEMBL21645800 0.67 GAA (0.62) GAAKDM4EALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE47689-E1 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2019-11-05 US disclosed
US-9617268-B2 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2017-04-11 US disclosed
US-20150119380-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY F. HOFFMANN-LA ROCHE AG (CH) 2015-04-30 US disclosed
EP-2797592-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC Therapeutics, Inc. (US) 2014-11-05 EP disclosed
WO-2013101974-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS, INC. (US) 2013-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150119380-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, RBM17, RBM22 GAA 447/4885KDM4E 829/4885ALDH1A1 1006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.